Litcius/Paper detail

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

B.J. Monk, Maria Pilar Barretina-Ginesta, Bhavana Pothuri, Ignace Vergote, Whitney A. Spannuth Graybill, Mansoor Raza Mirza, C. C. McCormick, Domenica Lorusso, Richard G. Moore, Gilles Freyer, Roisin E. O’Cearbhaill, Florian Heitz, David M. O’Malley, Andrés Redondo, Mark S. Shahin, Christof Vulsteke, William H. Bradley, Charlotte Aaquist Haslund, Dana M. Chase, Carmela Pisano, L.L. Holman, M.J. Rubio Pérez, Paul DiSilvestro, Lydia Gaba, Thomas J. Herzog, Ilan Bruchim, Natalie Compton, L. Shtessel, Izabela A. Malinowska, Antonio González-Martı́n

2024Annals of Oncology152 citationsDOIOpen Access PDF

Topics & Concepts

MedicineHazard ratioInternal medicinePopulationOncologyConfidence intervalProgression-free survivalOvarian cancerClinical endpointPlaceboMaintenance therapyChemotherapyRandomizationCancerRandomized controlled trialPathologyEnvironmental healthAlternative medicinePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentAdvanced Breast Cancer Therapies